Message #2 From:
Stock News Bot Date: July 25, 2006 09:00:00 AM
AMRN News Dutton Associates Announces Investment Opinion: Amarin Rating Raised To Strong Speculative Buy By Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--July 25, 2006--Dutton Associates continues coverage of Amarin Corporation plc (Nasdaq:AMRN), increasing its rating to Strong Speculative Buy and maintaining its price target of $4.50. The 15-page report by JM Dutton senior analyst Stephen Handley is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias and other leading financial portals.
Amarin Corporation plc is a neuroscience company focused on the research, development and commercialization of novel drugs for the treatment of central nervous system (CNS) disorders. We judge that Amarin's leading pipeline product, Miraxion(TM), which is undergoing Phase III clinical trials for the treatment of Huntington's disease (HD), has the potential to achieve U.S. sales in excess of $250 million for this application. It has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for HD and has received orphan drug status in the U.S. and Europe. In addition, this compound is in Phase II development for the treatment of depressive disorders and is one of two compounds that Amarin has in preclinical development for Parkinson's disease. We are favorably impressed with Amarin's outlook, for several reasons we discuss. Although the current product pipeline will not begin to be commercialized before early 2008, in the interim we believe that there are likely to be several catalysts to spark increased investor interest.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $52,000 from the Company for 8 Research Reports with coverage commencing on 9/22/2003. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
